Navigation Links
Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
Date:5/25/2011

EAST SETAUKET, N.Y., May 25, 2011 /PRNewswire/ -- John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc. (LIXT.PK), announces the appointment of  Robert B. Royds, M.B., B.S., M.R.C.P. to the company's Board of Directors.

Dr. Royds is Chair of the Board and Medical Director of Theradex Systems, Inc., a leading clinical research organization, which he founded in 1982.  Theradex®, based in Princeton, NJ, with research bases in Europe, Australia, and Japan, provides a full complement of services critical to drug development including regulatory strategy, consulting, pre-clinical toxicology and pharmacology review, preparation of regulatory filings, and clinical trials design.  Dr. Royds is responsible for the scientific affairs of the company.  

Trained in internal medicine and pharmacology, Dr. Royds has extensive experience in all stages of clinical drug development process. Before founding Theradex®, he was Senior Research Physician at Hoffmann-La Roche, Inc., and Associate Director for Clinical Pharmacology International at Merck, Sharp, and Dohme Research Laboratories. He has been a consultant/advisor to the National Institute of Child Health and Development and the National Cancer Institute on issues of clinical trial design and international standardization of data sets of clinical trials of new investigational anti-cancer agents. He has served as the physician-monitor for the Clinical Trials Monitoring Service of the National Cancer Institute since 1979, and has been the Principal Investigator for this contract since 1982.  

"We are extremely pleased that Dr. Royds has joined our Board of Directors.  He has had an exceptional experience in all aspects of cancer drug development, especially in the increasingly complex area of efficient clinical evaluation of new anti-cancer drugs with diverse clinical applications," said Dr. Kovach.  "Dr. Royds' expertise i
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lixte Biotechnology Holdings Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
2. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
3. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
4. Leading Ag Biotechnology Companies in Europe and America Save 50-80% of Field Study Management Time with eStudy
5. Goodwin Biotechnology and RAFAGEN Announce a Collaboration
6. Reportlinker Adds Industrial Biotechnology China News 1104
7. Novavax Named Biotechnology Firm of the Year by Tech Council of Maryland
8. Dyadic to Present at the World Congress on Industrial Biotechnology & Bioprocessing
9. Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
10. Reportlinker Adds Industrial Biotechnology China News 1103
11. Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or distribution (in ... where to do so would constitute a violation of the ... or the "Company") (LSE: SHP, NASDAQ: SHPG ) ... held a meeting with representatives of AbbVie. This ... or approval of AbbVie. A further update will ...
(Date:7/11/2014)... 11, 2014 BCC Research ( http://www.bccresearch.com ... POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the ... reached nearly $140 billion in 2013. This is estimated ... five-year compound annual growth rate (CAGR) of 28.6%. , ... interesting and exciting possibilities within the broader PCR field. ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/11/2014)... Cayenne Medical, Inc., a privately ... soft tissue reconstruction segment, announced the worldwide launch ... involving the shoulder and extremities. The SureLock System ... deployment method. The unique delivery eliminates manual tensioning ... or anchor displacement (also commonly know as anchor ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3
... Emisphere Technologies, Inc.,(Nasdaq: EMIS ), a biopharmaceutical ... therapeutic molecules using its eligen(R) technology,today announced that the ... on February 12, 2008 at the Waldorf Astoria Hotel ... Chief Executive Officer of,Emisphere, will present for the company ...
... Feb. 4 Pfizer,s loss of some top,talent, ... gain of two,Michigan companies teaming to help speed ... metastatic bone disease, rheumatoid arthritis and,osteoporosis., Velcura ... announced,his biotechnology company will work with Dr. Sliskovic ...
... Number of ... Patients, MALVERN, Pa., Feb. 4 Johns Hopkins ... in the United,States to install the newest magnetic resonance ... -- the,MAGNETOM(R) Verio. Combining 3 Tesla (T) strength and ...
Cached Biology Technology:Emisphere Technologies to Present at BIO CEO & Investor Conference on February 12 2Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease 2Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio 2Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio 3
(Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
(Date:7/11/2014)... demonstrated that transplantation of mesenchymal stem cells can stimulate ... models of Alzheimer,s disease (AD) and improve tissue and ... studies are reported on the therapeutic effect of adipose-derived ... on the effect on oxidative injury and neurogenesis in ... her team, School of Life Sciences, Tsinghua University, China ...
(Date:7/11/2014)... -- Research and Markets has announced the ... Industry Analysis Size Share Growth Trends and Forecast to ... http://photos.prnewswire.com/prnh/20130307/600769 The rising number ... for high level security in both private and public ... username and passwords, tokens etc. are vulnerable to attacks. ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... has provided new insight into the consequence of ... Prion and Alzheimer,s disease. Prion and Alzheimer,s ... mutations, or more commonly, interactions between an individual,s ... neurons to become misfolded or misrouted. In these ...
... have bacteria in their guts that may predispose them to ... University of California, Berkeley, and the University of Arizona, Tucson. ... than a thousand people from around the world showed that ... have been linked to obesity than did people living farther ...
... have shifted over the past 4 to 6 years, ... rose to the fore. Scientists who are leading advisors ... examine the state-of-the-science in "Research Challenges in Climate Change: ... 14 at the American Association for the Advancement of ...
Cached Biology News:New insight into protein misfolding in neurodegenerative disorders 2Geographic variation of human gut microbes tied to obesity 2Geographic variation of human gut microbes tied to obesity 3Hot issues in climate change research to be debated at AAAS Annual Meeting 2
... DMW143 taken from the SMZ line is a ... production and testing. It is available with a ... or a space-saving compact base (N2GG). This microscope ... and a projector all at the same time ...
... , Automatic grid, subgrid and spot finding overcome ... template assignment , ... Extensive background and signal options to optimize, ... results , Characterize more precisely ...
This is a PYREX replacement Allihn condenser with a 34/45 inner joint on the bottom for the No. CLS3840-S 125mL extractor system. The tubulation O.D. on the condenser is 10mm....
... contains 400 unique human proteins on ... The proteins, a cross section of ... quadruplicate for high-quality results. Additional control ... guarantee high validity and reproducibility., ,UNIchip ...
Biology Products: